160 related articles for article (PubMed ID: 30714704)
1. [Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].
Nihon Rinsho; 2016 Jul; 74 Suppl 5():565-9. PubMed ID: 30714704
[No Abstract] [Full Text] [Related]
2. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.
Yao Q; Bai Y; Orfao A; Kumar S; Chim CS
J Mol Diagn; 2020 May; 22(5):679-684. PubMed ID: 32151713
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of next-generation flow cytometry and next-generation sequencing in the assessment of minimal residual disease in multiple myeloma].
Wang QQ; Yao L; Zhu MQ; Yan LZ; Jin S; Shang JJ; Shi XL; Zhai YY; Yan S; Yao WQ; You HY; Wu DP; Fu CC
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):328-332. PubMed ID: 37357003
[No Abstract] [Full Text] [Related]
4. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
[TBL] [Abstract][Full Text] [Related]
5. Molecular Diagnostics of Plasma Cell Neoplasms.
Fitzpatrick MJ; Murali MR; Nardi V
Surg Pathol Clin; 2023 Jun; 16(2):401-410. PubMed ID: 37149365
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic value of minimal residual disease detection in multiple myeloma].
Takamatsu H
Nihon Rinsho; 2015 Jan; 73(1):69-73. PubMed ID: 25626307
[TBL] [Abstract][Full Text] [Related]
7. Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment.
Nishihori T; Song J; Shain KH
Curr Hematol Malig Rep; 2016 Apr; 11(2):118-26. PubMed ID: 26898557
[TBL] [Abstract][Full Text] [Related]
8. Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulation.
McAuliffe S; Brown R; Catalano A; Ho PJ; Nassif N; Woodland N; Hart D; Weatherburn C; Yang S; Suen H; Paul C; Joshua D; Gibson J
Leuk Lymphoma; 2015; 56(9):2714-6. PubMed ID: 25651422
[No Abstract] [Full Text] [Related]
9. Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma.
Bal S; Costa LJ
Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 1(1):1-20. PubMed ID: 33843859
[TBL] [Abstract][Full Text] [Related]
10. Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment.
Hultcrantz M; Rustad EH; Yellapantula V; Arcila M; Ho C; Syed MH; Papaemmanuil E; Zhang Y; Maura F; Landgren O
Blood Cancer J; 2020 Jul; 10(7):76. PubMed ID: 32699232
[No Abstract] [Full Text] [Related]
11. Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma.
Medina A; Jiménez C; Puig N; Sarasquete ME; Flores-Montero J; García-Álvarez M; Prieto-Conde I; Chillón C; Alcoceba M; González-Calle V; Gutiérrez NC; Jacobsen A; Vigil E; Hutt K; Huang Y; Orfao A; González M; Miller J; García-Sanz R
Arch Pathol Lab Med; 2022 Jul; 146(7):862-871. PubMed ID: 34619755
[TBL] [Abstract][Full Text] [Related]
12. Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients.
Ha J; Lee H; Shin S; Cho H; Chung H; Jang JE; Kim SJ; Cheong JW; Lee ST; Kim JS; Choi JR
J Mol Diagn; 2022 Jan; 24(1):48-56. PubMed ID: 34656761
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium.
Landgren O; Gormley N; Turley D; Owen RG; Rawstron A; Paiva B; Barnett D; Arroz M; Wallace P; Durie B; Yuan C; Dogan A; Stetler-Stevenson M; Marti GE
Am J Hematol; 2014 Dec; 89(12):1159-60. PubMed ID: 25132630
[No Abstract] [Full Text] [Related]
14. Minimal residual disease analysis in myeloma - when, why and where.
Yanamandra U; Kumar SK
Leuk Lymphoma; 2018 Aug; 59(8):1772-1784. PubMed ID: 29019452
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use.
Maclachlan KH; Came N; Diamond B; Roshal M; Ho C; Thoren K; Mayerhoefer ME; Landgren O; Harrison S
Pathology; 2021 Apr; 53(3):385-399. PubMed ID: 33674146
[TBL] [Abstract][Full Text] [Related]
16. Molecular detection of minimal residual disease in multiple myeloma.
Bai Y; Orfao A; Chim CS
Br J Haematol; 2018 Apr; 181(1):11-26. PubMed ID: 29265356
[TBL] [Abstract][Full Text] [Related]
17. Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma.
Rustad EH; Hultcrantz M; Yellapantula VD; Akhlaghi T; Ho C; Arcila ME; Roshal M; Patel A; Chen D; Devlin SM; Jacobsen A; Huang Y; Miller JE; Papaemmanuil E; Landgren O
PLoS One; 2019; 14(3):e0211600. PubMed ID: 30901326
[TBL] [Abstract][Full Text] [Related]
18. Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia.
Levine RL; Valk PJM
Haematologica; 2019 May; 104(5):868-871. PubMed ID: 30923100
[No Abstract] [Full Text] [Related]
19. Multiple myeloma: disease response assessment.
Zamagni E; Tacchetti P; Terragna C; Cavo M
Expert Rev Hematol; 2016 Sep; 9(9):831-7. PubMed ID: 27409577
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease detection of myeloma using sequencing of immunoglobulin heavy chain gene VDJ regions.
Ho C; Arcila ME
Semin Hematol; 2018 Jan; 55(1):13-18. PubMed ID: 29759147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
